Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation.
This preclinical study examined how survodutide — a dual glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R) agonist in clinical development for obesity and MASH — acts in the brain to reduce body weight. Researchers first mapped GCGR and GLP-1R expression in human and mouse circumventricular organs (CVOs), finding that GCGR is barely detectable in the area postrema (AP) and arcuate nucleus of the hypothalamus (ARH), whereas GLP-1R is expressed in both regions. Using a fluorophore-labeled version of survodutide in mice, the study found that the compound accesses CVOs and nearby hypothalamic and hindbrain nuclei directly, without evidence of broadly crossing the blood-brain barrier. C-Fos activation mapping showed that survodutide activated multiple brain nuclei associated with food intake control. A long-acting GCGR-selective agonist, by contrast, did not activate satiety-related brain regions or reduce food intake, though it did reduce body weight, suggesting the appetite-suppressing effects of survodutide are primarily GLP-1R dependent. Limitations include the exclusively preclinical (mouse) design and the use of a labeled surrogate compound. The authors conclude the findings support a dual mechanism for survodutide's weight-lowering effects.